Affiliation:
1. Department of Hematology Japanese Red Cross Medical Center Tokyo Japan
2. Department of Pharmacy Japanese Red Cross Medical Center Tokyo Japan
Abstract
AbstractTo retrospectively analyze whether the second revision of the international staging system (R2‐ISS) influenced prognosis at treatment initiation in patients with multiple myeloma (MM) receiving anti‐CD38 antibody‐based triplet treatments. High‐risk chromosomal abnormalities were examined from diagnosis to treatment initiation and considered positive if detected once. R2‐ISS was recalculated at the initiation of treatment and defined as “dynamic R2‐ISS." Data from 150 patients who underwent the defined treatments were analyzed. The median progression‐free survival (PFS) was 19.5 months, and the median overall survival (OS) was 36.5 months. Dynamic R2‐ISS significantly stratified prognoses for both PFS and OS. The median PFS for patients with dynamic R2‐ISS IV was 3.3 months, and the median OS was 11.7 months, indicating extremely poor outcomes. Although the Revised International Staging System (R‐ISS) calculated at the initiation of treatment significantly stratified treatment outcomes, the patients classified as R‐ISS could be further stratified by R2‐ISS to provide better prognostic information. Dynamic R2‐ISS showed potential as a prognostic tool in patients with MM who are treated with anti‐CD38 antibody‐based triplet therapies.